Abstract:The use of IVIG plus corticosteroids is cost saving compared with treatment with immunosuppressant plus corticosteroids in Thai patients with steroid-refractory DM. Policy makers should consider using our findings in their decision-making process for adding IVIG to corticosteroids as the second-line therapy for steroid-refractory DM patients.
“…Thus, IVIG treatment could potentially be associated with significant decrease in glucocorticoid‐ and immunosuppressive‐induced morbidity, which may translate into further healthcare savings favouring IVIG use. A recent study showed that IVIG plus glucocorticoids is cost‐effective for managing steroid‐refractory DM compared with immunosuppressive medications plus glucocortiocoids …”
Section: Discussionmentioning
confidence: 99%
“…A recent study showed that IVIG plus glucocorticoids is cost-effective for managing steroid-refractory DM compared with immunosuppressive medications plus glucocortiocoids. 20…”
Use of IVIG resulted in improvement of refractory cutaneous DM in the vast majority of patients relatively soon after initiation and regardless of DM subtype or clinical manifestations. Additionally, IVIG allowed decrease or discontinuation of immunosuppressive medications in 80% of patients. These findings suggest that IVIG can be a clinically efficacious and cost-effective treatment for refractory cutaneous DM and warrants prospective study.
“…Thus, IVIG treatment could potentially be associated with significant decrease in glucocorticoid‐ and immunosuppressive‐induced morbidity, which may translate into further healthcare savings favouring IVIG use. A recent study showed that IVIG plus glucocorticoids is cost‐effective for managing steroid‐refractory DM compared with immunosuppressive medications plus glucocortiocoids …”
Section: Discussionmentioning
confidence: 99%
“…A recent study showed that IVIG plus glucocorticoids is cost-effective for managing steroid-refractory DM compared with immunosuppressive medications plus glucocortiocoids. 20…”
Use of IVIG resulted in improvement of refractory cutaneous DM in the vast majority of patients relatively soon after initiation and regardless of DM subtype or clinical manifestations. Additionally, IVIG allowed decrease or discontinuation of immunosuppressive medications in 80% of patients. These findings suggest that IVIG can be a clinically efficacious and cost-effective treatment for refractory cutaneous DM and warrants prospective study.
“…Using IVIG products that are low in IgA content may decrease these side effects (94). For steroid resistant patients with DM, the use of IVIG + corticosteroids was cost saving (95). Replacement IgG may be required, after rituximab treatment (see below) if the child develops a significantly low level of IgG (96).…”
Section: Childhood and Adult Onset Dermatomyositis Have Differing Feamentioning
“…Previous studies have analyzed the costs of specific treatments associated with dermatomyositis , evaluated burden by different metrics, e.g., health resource and work loss , or measured costs in other countries . In addition, most of these other studies have evaluated aggregate burden of inflammatory myopathies (e.g., dermatomyositis and polymyositis) rather than dermatomyositis in isolation.…”
There is a significant and increasing inpatient burden for dermatomyositis in the US. There appear to be racial differences, as nonwhites have higher prevalence of admission, increased LOS, and cost of care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.